Biotech IPO Tracker 2026
Live tracker of biotech/biopharma IPOs in 2026 — therapeutic area, lead asset + phase at IPO, pricing date, proceeds and valuation, plus aftermarket performance.
Last updated:
10 Feb 2026
Get 2026 biotech IPO updates as they land (free)
The tracker refreshes weekly — the BioBucks newsletter flags IPO filings, launches, pricings and aftermarket moves daily (in ~5 mins).
Read by 2,000+ VC, bankers, BD&L, and public biotech investors. No spam. Unsubscribe anytime.
IPOs
|
Company Name
|
Therapeutic Area
|
Lead Asset
|
Phase at IPO
|
Pricing Date
|
Offer Price
|
IPO Proceeds
|
Valuation (MCAP)
|
1 day (%)
|
Offer to current (%)
|
| Aktis Oncology |
Oncology (radiopharma) |
[225Ac]Ac-AKY-1189 (Nectin-4+ solid tumors) |
Phase 1b |
08-Jan-2026 |
$18.00 |
$318M (≈$365M incl. option) |
Up to ~$945M (implied) |
+24.4% |
-1.1% |
| Veradermics |
Aesthetic dermatology |
VDPHL01 (extended-release oral minoxidil; androgenetic alopecia) |
Phase 3 |
03-Feb-2026 |
$17.00 |
$256M (≈$295M incl. option) |
~$596M (at IPO price) |
+122.1% |
+137.9% |
| Eikon Therapeutics |
Oncology |
EIK1001 (TLR7/8 agonist; advanced melanoma) |
Phase 2/3 |
04-Feb-2026 |
$18.00 |
$381M |
~$860M (at debut) |
-16.7% |
-24.5% |
| Agomab Therapeutics |
Inflammation / Fibrosis |
AGMB-129 / ontunisertib (oral ALK5 inhibitor; fibrostenosing Crohn’s) |
Phase 2a |
05-Feb-2026 |
$16.00 |
$200M |
~$716M (at debut) |
-8.4% |
-2.8% |
| SpyGlass Pharma |
Ophthalmology |
BIM-IOL System (bimatoprost drug-pad IOL; OAG/OHT) |
Phase 3 |
05-Feb-2026 |
$16.00 |
$150M (≈$173M incl. option) |
~$842M (IPO-day close mcap) |
+65.0% |
+73.9% |
| Generate Biomedicines |
Inflammation / Respiratory |
GB-0895 (long-acting anti-TSLP mAb; severe asthma) |
Phase 3 |
Filed 04-Feb-2026 |
N/A |
Up to $100M (filed) |
Coming soon |
Coming soon |
Coming soon |
Want IPO alerts as they land?
The tracker refreshes weekly — the BioBucks newsletter flags filings, launches, pricings and aftermarket movers daily (in ~5 mins).
Join 2,000+ VC, bankers, and public biotech investors. No spam. Unsubscribe anytime.
